Company Overview - PetMed Express, Inc. is an online pet pharmacy that provides prescription and non-prescription medications, supplements, and pet supplies directly to consumers across the United States [3]. Allegations and Stock Impact - On June 10, 2025, PetMed announced a delay in releasing its fourth-quarter and full-year 2025 earnings due to the need for additional time to complete its year-end audit process, resulting in a stock price decline of $0.47, or 11.2%, closing at $3.72 per share on June 11, 2025 [3]. - On July 1, 2025, PetMed disclosed another delay in filing its annual report with the SEC, linked to an internal investigation by the Audit Committee regarding whistleblower complaints about revenue recognition, promotional coupon impacts, and company culture. This announcement led to a further stock price drop of $0.05, or 1.51%, closing at $3.27 per share on the same day [3]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving PetMed, stemming from allegations of providing misleading business information to investors [1].

Core Viewpoint - PetMed Express, Inc. has announced preliminary financial results for the fourth quarter and fiscal year 2025, indicating a significant decline in net sales and an increase in net loss compared to the previous year [1][2][3]. Financial Performance - For the fiscal fourth quarter ended March 31, 2025, net sales are estimated to be between $51.1 million and $53.1 million, down from $66.5 million in the prior year [2]. - The estimated net loss for the fourth quarter is between $9.9 million and $10.4 million, compared to a net loss of $5.0 million in the prior year [2]. - For the fiscal year ended March 31, 2025, net sales are estimated to range from $231.6 million to $233.6 million, a decrease from $281.1 million in the prior year [3]. - The estimated net loss for the fiscal year is between $4.5 million and $5.0 million, an improvement from a net loss of $7.5 million in the prior year [3]. - The net loss includes a tax expense impact of $6.4 million due to a valuation allowance on the Company's net deferred tax assets [2][3]. Cash Position - As of March 31, 2025, the Company reported $54.7 million in cash and no debt [4]. Filing Status - The Company has filed Form 12b-25 with the SEC, indicating it is unable to file its Annual Report on Form 10-K within the prescribed time period, but expects to do so by July 1, 2025 [1][5].

Core Viewpoint - PetMed Express, Inc. will hold a conference call to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025, on June 10, 2025 [1][2]. Company Overview - PetMed Express, Inc., operating as PetMeds, is a pioneer in the direct-to-consumer pet healthcare sector, founded in 1996 [3]. - The company is a licensed national online pharmacy across all 50 states, providing a range of pet health solutions including pharmaceuticals, compounded medications, and OTC supplements [3]. - PetMeds aims to empower pet owners to enhance the health and longevity of their pets through value, convenience, and care [3]. Conference Call Details - The conference call is scheduled for June 10, 2025, at 4:30 PM Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants are encouraged to dial in 5-10 minutes prior to the start time using the provided U.S. and international numbers [2]. - A telephonic replay of the conference call will be available after 7:30 PM Eastern Time on the same day until June 24, 2025 [2][3].